Sutro Biopharma (STRO) Revenue (2017 - 2026)

Sutro Biopharma has reported Revenue for 9 years, with the latest figure at $6.6 million in Q4 2025.

• Quarterly Revenue fell 55.43% year-over-year to $6.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $97.4 million (up 57.05% YoY) and the FY2025 annual result came in at $102.5 million, up 65.18% from the prior year.
• Revenue slipped to $6.6 million in Q4 2025 per STRO's latest filing, from $9.7 million in the prior quarter.
• Over five years, Revenue peaked at $113.7 million in Q4 2023 and troughed at $5.9 million in Q1 2022.
• A 5-year average of $22.1 million and a median of $13.8 million in 2021 frame the typical range for Revenue.
• The sharpest annual moves came in 2023 and 2024: Revenue surged 1217.44% in 2023, then slumped 86.98% in 2024.
• Over 5 years, Revenue stood at $10.7 million in 2021, then retreated by 18.98% to $8.6 million in 2022, then soared by 1217.44% to $113.7 million in 2023, then plunged by 86.98% to $14.8 million in 2024, then sank by 55.43% to $6.6 million in 2025.
• According to Business Quant data, Revenue over the past three periods registered $6.6 million, $9.7 million, and $63.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.